1-9 of 9
Denise Trone
Close
Sort by
Journal Articles

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3 -ITD–mutated, relapsed or refractory AML

Clinical Trials & Observations
Jorge E. Cortes, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean-Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis
Journal: Blood
Blood (2018) 132 (6): 598–607.
https://doi.org/10.1182/blood-2018-01-821629
Published: 2018
Includes: Supplemental data
Journal Articles

Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-Itd-Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Mark J. Levis, MD PhD, Jorge E. Cortes, MD, Guy M. Gammon, MBBS, MRCP, Denise Trone, Dongwoo Kang, Jianke Li
Journal: Blood
Blood (2016) 128 (22): 4042.
https://doi.org/10.1182/blood.V128.22.4042.4042
Published: 2016
Journal Articles

Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data)

Robert K Hills, DPhil, Guy Gammon, MBBS,MRCP, Denise Trone, Alan K. Burnett, MD FRCP
Journal: Blood
Blood (2015) 126 (23): 2557.
https://doi.org/10.1182/blood.V126.23.2557.2557
Published: 2015
Journal Articles

Results of a Phase 1 Study of Quizartinib (AC220) As Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Cell Transplantation

Brenda M. Sandmaier, MD, Samer K Khaled, MD, Betul Oran, MD, Guy Gammon, MD, Denise Trone, Olga Frankfurt, MD
Journal: Blood
Blood (2014) 124 (21): 428.
https://doi.org/10.1182/blood.V124.21.428.428
Published: 2014
Journal Articles

Results Of a Phase 2 Randomized, Open-Label, Study Of Lower Doses Of Quizartinib (AC220; ASP2689) In Subjects With FLT3-ITD Positive Relapsed Or Refractory Acute Myeloid Leukemia (AML)

Jorge E. Cortes, MD, Martin S Tallman, MD, Gary Schiller, MD, Denise Trone, Guy Gammon, MD, Stuart Goldberg, MD, Alexander E Perl, MD, Jean-Pierre Marie, MD, Giovanni Martinelli, Mark Levis, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 494.
https://doi.org/10.1182/blood.V122.21.494.494
Published: 2013
Journal Articles

Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Jessica K Altman, MD, James M. Foran, MD, Keith W. Pratz, MD, Denise Trone, Guy Gammon, MD, Jorge E. Cortes, MD, Martin S Tallman, MD
Journal: Blood
Blood (2013) 122 (21): 623.
https://doi.org/10.1182/blood.V122.21.623.623
Published: 2013
Journal Articles

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, James M. Foran, MD, FRCPC, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, M.D., Guy Gammon, MD, Denise Trone, Robert C Armstrong, Ph.D., Joyce James, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1507.
https://doi.org/10.1182/blood.V120.21.1507.1507
Published: 2012
Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Alexander E Perl, MD, Hervé Dombret, MD, Sabine Kayser, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Mark J. Levis, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 48.
https://doi.org/10.1182/blood.V120.21.48.48
Published: 2012
Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation

Mark J. Levis, MD, PhD, Alexander E Perl, MD, Hervé Dombret, MD, Hartmut Döhner, MD, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Jorge E Cortes, MD
Journal: Blood
Blood (2012) 120 (21): 673.
https://doi.org/10.1182/blood.V120.21.673.673
Published: 2012